Free MIMS diabetes workshops - last few places remaining

Join MIMS at the 'Type 2 diabetes: getting to the heart of the matter' event series running throughout November and early December.

The free full-day educational programme will enhance your understanding of key aspects of short-term and long-term management of patients with diabetes, discuss approaches to managing clinical inertia and review the current prescribing landscape and guidelines for type 2 diabetes.

The programme will be delivered by expert speakers and offers the opportunity to earn 5 hours of CPD credits. There are 9 locations to choose from. 

The event series kicks off on Thursday, 1st November 2018 in Cardiff at the Marriott Hotel, Mill Lane Cardiff, CF10 1EZ.

The Cardiff event will be chaired by Professor Steve Bain, Professor in Medicine (Diabetes), Swansea University Medical School, and he will be joined by:

  • Su Down, Diabetes Nurse Consultant, Somerset
  • Dr Marc Evans, Consultant Diabetologist, Cardiff University
  • Professor Peter Evans, Senior Consultant in Diabetes and Endocrinology, Royal Gwent Hospital, Newport
  • Sian Bodman, Senior Diabetes Nurse, Aneurin Bevan University Health Board

A few places are still available. Click here to view the agenda and book yours today.

This MIMS workshop has been initiated, funded and reviewed by Napp Pharmaceuticals.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

A careful stepwise approach is needed when reducing...

Prescribers advised not to use newer anticoagulants in patients with antiphospholipid syndrome
Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...